Dexcom Wins Access to Dexcom ONE for 100,000 People Living With Type 2 Diabetes
June 04 2024 - 10:16AM
Business Wire
DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time
continuous glucose monitoring for people with diabetes, today
announced a significant advancement in access to its products for
those treating Type 2 diabetes (T2D) with basal insulin injections.
The company, which pioneered CGM technology 25 years ago, has
secured access to its Dexcom ONE sensor for around 100,000 T2D
users in France. The reimbursement guidance offers people aged over
two years who are on non-intensified insulin therapy (less than 3
injections a day) and whose glycaemic control is insufficient
(HbA1c ≥ 8%) access to Dexcom’s life-changing technology. The
French government is the first in Europe to offer full national
reimbursement for Dexcom CGM technology to those treating T2D with
basal injections, following other countries around the world such
as the USA and New Zealand.
The French reimbursement news is part of worldwide growing
awareness by governments and healthcare providers of the impact
that rising diagnoses of T2D have on both national healthcare
services and those living with the condition. Governments and
healthcare providers are increasingly looking to technology, such
as Dexcom CGM, for a solution, as studies demonstrate both the
health benefits of CGM for T2D and the potential cost savings for
health services1-5. Dexcom also recently secured reimbursement of
its sensors in Germany with health insurance provider KKH for those
living with Type 2 diabetes and receiving Basal Oral Therapy.
“The decision by the French government to offer national
reimbursement for Dexcom CGM to those treating their Type 2
diabetes with basal insulin injections is a significant step
forward in both the treatment and understanding of Type 2 diabetes
on both an individual and societal level,” said Alex Moussa, Senior
Vice President and General Manager of Dexcom EMEA & LATAM. “We
will continue to advocate for widening access to our life-changing
technology for those living with Type 2 diabetes. The science and
economics are clear: our technology can significantly improve the
management of Type 2 diabetes, positively impact the lives of those
living with the condition, and lead to cost savings for healthcare
services.”
The management of T2D is a hot topic around the world as
diagnoses of the condition continue to steadily grow, with Western
European countries seeing some of the fastest growth rates*6. The
impact on the lives of those living with the condition is also
becoming clearer. A recent, first-of-its-kind survey by Dexcom of
those living with T2D in the UK showed that 63% of respondents
encountered difficulties managing their diabetes, and 83% of
respondents were open to using CGM technology to help manage their
T2D7.
However, while the use of CGM technology to help manage T2D is
on the rise, it remains an underutilised technology. The same
survey showed that although those living with the condition were
keen to turn to technology for a solution, prescribing CGM for T2D
is not standard practice among healthcare professionals. Across the
spectrum of T2D users, only 39% had used the technology. With T2D
growing worldwide, a willingness among people with T2D to use tech
to manage the condition, and growing evidence that CGM usage, such
as Dexcom CGM, can improve lives and save money, France's
leadership strengthens the case for additional countries to expand
access to Dexcom technology for people with Type 2 diabetes.
*2017 6059 cases of T2 diabetes per 100,000 people, expected to
reach 7079 per 100,000 by 2030.
1 Alshannaq H et al Cost-utility of real-time continuous glucose
monitoring versus self-monitoring of blood glucose in people with
insulin-treated Type II diabetes in France. J Comp Eff Res. 2024;
13(3):e230174. 2 Isitt JJ, et al. Cost-Effectiveness of a Real-Time
Continuous Glucose Monitoring System Versus Self-Monitoring of
Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in
the UK. Diabetes Ther. 2022; 13(11-12):1875-90. 3 Dexcom, Data on
File 2024. 4 Reaven, P. Initiating Continuous Glucose Monitoring
(CGM) in Adult-Onset Type 1 and Type 2 Diabetes Reduces Mortality.
Presented at ATTD, 2024; March 9th. Florence, Italy. 5 Clark T et
al. Diabetes Technol Ther. 2024. doi: 10.1089/dia.2023.0612. 6 Khan
MAB et al J Epidemiol Glob Health. 2020 Mar;10(1):107-111. 7 Dexcom
and Censuswide online survey of people living with diabetes (Type
2, their caretakers and healthcare practitioners), conducted in the
UK, H1 2024, N=852, PWD = 251, HCP = 351, Caretakers = 250
Category: IR
About DexCom, Inc.
DexCom, Inc. empowers people to take real-time control of health
through innovative continuous glucose monitoring (CGM) systems.
Headquartered in San Diego, Calif., and with operations across
Europe and select parts of Asia/Oceania, Dexcom has emerged as a
leader of diabetes care technology. By listening to the needs of
users, caregivers, and providers, Dexcom works to simplify and
improve diabetes management around the world. For more information
about Dexcom CGM, visit www.dexcom.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240604408592/en/
Gemma McDonald +44 (0) 7552 368398 gemma.mcdonald@dexcom.com
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Dec 2024 to Jan 2025
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Jan 2024 to Jan 2025